<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075218</url>
  </required_header>
  <id_info>
    <org_study_id>A6181004</org_study_id>
    <nct_id>NCT00075218</nct_id>
    <nct_alias>NCT00085618</nct_alias>
  </id_info>
  <brief_title>A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal
      stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to
      imatinib treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase</measure>
    <time_frame>Day 28 of each 6-week cycle : duration of double-blind treatment phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study</measure>
    <time_frame>Day 28 of each 6-week cycle : duration of double-blind treatment phase after Last Subject Last Visit (LSLV)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Status of Subjects</measure>
    <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Based on the Rank Preserving Structural Failure Time Method</measure>
    <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Tumor Response During Double-blind Treatment Phase</measure>
    <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response (CR or PR) in Subjects</measure>
    <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Performance Status Maintenance</measure>
    <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Progression Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</measure>
    <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</measure>
    <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Score in EuroQoL Visual Analog Scale (EQ-VAS)</measure>
    <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Health State Profile Index</measure>
    <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU011248</intervention_name>
    <description>50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation
             or combined modality treatment with curative intent

          -  Failed Gleevec treatment or intolerant to Gleevec therapy

        Key Exclusion Criteria:

          -  Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or
             investigational agent since the last dose of Gleevec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columubs</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <state>Gr</state>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L'Hospitalet del Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181004&amp;StudyName=A%20Study%20To%20Assess%20The%20Safety%20And%20Efficacy%20Of%20SU11248%20In%20Patients%20With%20Gastrointestinal%20Stromal%20Tumors%20%28GIST%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2004</study_first_submitted>
  <study_first_submitted_qc>January 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2004</study_first_posted>
  <results_first_submitted>May 6, 2009</results_first_submitted>
  <results_first_submitted_qc>August 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2009</results_first_posted>
  <last_update_submitted>August 31, 2009</last_update_submitted>
  <last_update_submitted_qc>August 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment began (medical clinic) in December 2003. Study was unblinded on 27 January 2005 (end of Double-blind treatment). Subjects experiencing disease progression could crossover to Open-label treatment. Open-label data collection ended May 2008.</recruitment_details>
      <pre_assignment_details>361 subjects randomized to double-blind treatment in 2:1 ratio (sunitinib vs. Placebo).
255 subjects continued on or crossed over to Open-label treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib Double-Blind Treatment</title>
          <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Double-Blind Treatment</title>
          <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
        </group>
        <group group_id="P3">
          <title>Sunitinib Open-Label Treatment</title>
          <description>Subjects experiencing disease progression could have their treatment assignment unblinded, and subjects who had been receiving placebo could crossover to open-label treatment with sunitinib; subjects who had been receiving sunitinib during double-blind treatment of the study could continue to do so after unblinding if, in the opinion of the investigator, there was sufficient evidence of clinical benefit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="243">Intent To Treat Population (ITT)</participants>
                <participants group_id="P2" count="118">Intent To Treat Population (ITT)</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Double-Blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="228">As Treated Population (AT)</participants>
                <participants group_id="P2" count="114">As Treated Population (AT)</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Crossed Over to Open-Label Treatment</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152">Defined:subjects completed double-blind treatment phase and/or entered open-label treatment phase.</participants>
                <participants group_id="P2" count="103">Defined:subjects completed double-blind treatment phase and/or entered open-label treatment phase.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision of Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No study medication taken</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="255"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="174"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision of Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>enrolled in a separate continuation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib Double-Blind Treatment</title>
          <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Double-Blind Treatment</title>
          <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="243"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="361"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="251.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="162.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="199.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase</title>
        <description>Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).</description>
        <time_frame>Day 28 of each 6-week cycle : duration of double-blind treatment phase</time_frame>
        <population>From the Intent to Treat (ITT) population, 82 subjects on sunitinib treatment were observed to have disease progression during blinded phase and were included in TTP analysis. 67 subjects on placebo were observed to have disease progression during blinded phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase</title>
          <description>Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).</description>
          <population>From the Intent to Treat (ITT) population, 82 subjects on sunitinib treatment were observed to have disease progression during blinded phase and were included in TTP analysis. 67 subjects on placebo were observed to have disease progression during blinded phase.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="16.0" upper_limit="32.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed to test the null hypothesis that the median TTP from placebo treatment is 4 months versus the alternative hypothesis that the median TTP from sunitinib treatment is at least 6 months with an overall 2-sided significance level of 0.05 and power of 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The nominal levels of significance for the interim and final analyses were determined at the time of the analyses using the Lan-DeMets procedure with an O’Brien-Fleming stopping rule.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>two-sided unstratified log-rank test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.329</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.233</ci_lower_limit>
            <ci_upper_limit>0.466</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Time from randomization to first documentation of objective tumor progression or to death due to any cause (on treatment or within 28 days of last dose).</description>
        <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Time from randomization to first documentation of objective tumor progression or to death due to any cause (on treatment or within 28 days of last dose).</description>
          <population>ITT population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="10.9" upper_limit="28.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.4" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No p-value adjustment for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.347</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.253</ci_lower_limit>
            <ci_upper_limit>0.475</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Status of Subjects</title>
        <description>Number of subjects alive at end of study.</description>
        <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Status of Subjects</title>
          <description>Number of subjects alive at end of study.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from date of randomization to date of death due to any cause.</description>
        <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
        <population>ITT population; Number subjects Dead = 176, 90 (sunitinib, placebo respectively). Subjects who were not known to be dead at the time the database was closed for analysis were censored on the date they were last known to be alive.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from date of randomization to date of death due to any cause.</description>
          <population>ITT population; Number subjects Dead = 176, 90 (sunitinib, placebo respectively). Subjects who were not known to be dead at the time the database was closed for analysis were censored on the date they were last known to be alive.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="61.3" upper_limit="83.0"/>
                    <measurement group_id="O2" value="64.9" lower_limit="45.7" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>No p-value adjustment for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.876</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.679</ci_lower_limit>
            <ci_upper_limit>1.129</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Based on the Rank Preserving Structural Failure Time Method</title>
        <description>time from date of randomization to date of death due to any cause (rank preserving structural failure time method).</description>
        <time_frame>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Based on the Rank Preserving Structural Failure Time Method</title>
          <description>time from date of randomization to date of death due to any cause (rank preserving structural failure time method).</description>
          <population>ITT population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="61.3" upper_limit="83.0"/>
                    <measurement group_id="O2" value="39.0" lower_limit="28.0" upper_limit="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>No p-value adjustment for multiple comparisons.</p_value_desc>
            <method>Rank Preserving Structural Failure Time</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.505</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.262</ci_lower_limit>
            <ci_upper_limit>1.134</ci_upper_limit>
            <estimate_desc>95% CI for Hazard Ratio is from 2.5% and 97.5% Empirical Percentiles of 100,000 Bootstraps.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Tumor Response During Double-blind Treatment Phase</title>
        <description>Tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Tumor Response During Double-blind Treatment Phase</title>
          <description>Tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to Evaluate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Objective Response (CR or PR) in Subjects</title>
        <description>Overall confirmed objective response = confirmed Complete Response (CR) OR confirmed Partial Response (PR) according to RECIST. Confirmed responses were those that persisted on repeat imaging study ≥ 4 weeks after initial documentation of response.</description>
        <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Objective Response (CR or PR) in Subjects</title>
          <description>Overall confirmed objective response = confirmed Complete Response (CR) OR confirmed Partial Response (PR) according to RECIST. Confirmed responses were those that persisted on repeat imaging study ≥ 4 weeks after initial documentation of response.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>rate (percentage)</param_type>
            <param_value>6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
            <estimate_desc>Used exact method based on binomial distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>No p-value adjustment for multiple comparisons.</p_value_desc>
            <method>Pearson chi-square test</method>
            <param_type>Treatment Difference (%)</param_type>
            <param_value>6.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.47</ci_lower_limit>
            <ci_upper_limit>9.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Response (TTR)</title>
        <description>Time from date of randomization to first documentation of objective tumor response that was subsequently confirmed. TTR was only calculated for the subgroup of subjects with a confirmed objective tumor response.</description>
        <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT population. Number of subjects analyzed = number of subjects with tumor response.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Response (TTR)</title>
          <description>Time from date of randomization to first documentation of objective tumor response that was subsequently confirmed. TTR was only calculated for the subgroup of subjects with a confirmed objective tumor response.</description>
          <population>ITT population. Number of subjects analyzed = number of subjects with tumor response.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="9.9" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Performance Status Maintenance</title>
        <description>Time from randomization until the last time the performance status was no worse than at baseline or to death due to cancer in the absence of previous documentation of performance status worsening.</description>
        <time_frame>Day 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT Population. Number of subjects at median observed to have status worsening or died before status worsening.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Performance Status Maintenance</title>
          <description>Time from randomization until the last time the performance status was no worse than at baseline or to death due to cancer in the absence of previous documentation of performance status worsening.</description>
          <population>ITT Population. Number of subjects at median observed to have status worsening or died before status worsening.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="12.1" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study</title>
        <description>Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).</description>
        <time_frame>Day 28 of each 6-week cycle : duration of double-blind treatment phase after Last Subject Last Visit (LSLV)</time_frame>
        <population>From the Intent to Treat (ITT) population, 91 subjects on sunitinib treatment were observed to have disease progression during blinded phase and were included in TTP analysis. 73 subjects on placebo were observed to have disease progression during blinded phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study</title>
          <description>Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).</description>
          <population>From the Intent to Treat (ITT) population, 91 subjects on sunitinib treatment were observed to have disease progression during blinded phase and were included in TTP analysis. 73 subjects on placebo were observed to have disease progression during blinded phase.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="16.0" upper_limit="32.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>two-sided unstratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.339</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.244</ci_lower_limit>
            <ci_upper_limit>0.472</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified log-rank test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>log—rank test of treatment stratified by prior imatinib mesylate response and McGill Pain Questionnaire's Present Pain Intensity score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.327</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.232</ci_lower_limit>
            <ci_upper_limit>0.460</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Progression Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</title>
        <description>25th Quartile: Time to Progression. Progression: a) No change (NC) in MPQ-PPI score (0=no pain to 5=excruciating pain) with increase total analgesic use &gt;= 50% over baseline OR b) Increase score &gt;= 1 point with either NC in total analgesic use or increase total analgesic use &gt;= 50% over baseline. (50th Quartile not achieved.)</description>
        <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>Pain-Relief-Response population. Subjects at 25th Quartile with pain progress during blinded phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Progression Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</title>
          <description>25th Quartile: Time to Progression. Progression: a) No change (NC) in MPQ-PPI score (0=no pain to 5=excruciating pain) with increase total analgesic use &gt;= 50% over baseline OR b) Increase score &gt;= 1 point with either NC in total analgesic use or increase total analgesic use &gt;= 50% over baseline. (50th Quartile not achieved.)</description>
          <population>Pain-Relief-Response population. Subjects at 25th Quartile with pain progress during blinded phase.</population>
          <units>weeks (25th Quartile)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="6.1" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9322</p_value>
            <method>Log Rank</method>
            <method_desc>2-sided, unstratified log-rank test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.508</ci_lower_limit>
            <ci_upper_limit>1.860</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</title>
        <description>MPQ-PPI: 0=no pain to 5= excruciating pain. Pain Relief Response= 1) Decrease by &gt;= 1 points in MPQ-PPI score with either Decrease or No Change in total analgesic use &gt;= 50% over baseline OR 2) No change in MPQ-PPI score with Decrease total analgesic use &gt;= 50% over baseline.</description>
        <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>Pain-Relief-Response population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</title>
          <description>MPQ-PPI: 0=no pain to 5= excruciating pain. Pain Relief Response= 1) Decrease by &gt;= 1 points in MPQ-PPI score with either Decrease or No Change in total analgesic use &gt;= 50% over baseline OR 2) No change in MPQ-PPI score with Decrease total analgesic use &gt;= 50% over baseline.</description>
          <population>Pain-Relief-Response population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>Pearson chi-square</method>
            <param_type>Treatment Difference (percent)</param_type>
            <param_value>17.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.7</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
            <estimate_desc>95% CI of Difference based on normal distribution. Percent = (number of subjects with response per total subjects per treatment in defined analysis population)*100.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Score in EuroQoL Visual Analog Scale (EQ-VAS)</title>
        <description>Change: median score at observation minus median score at baseline. EQ-VAS score on the self-rated “thermometer,” indicating the patient's own assessment of their health status from 0 (worst) to 100 (best) imaginable health state.</description>
        <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT population. Number subjects with evaluable data: (n=sunitinib, placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Score in EuroQoL Visual Analog Scale (EQ-VAS)</title>
          <description>Change: median score at observation minus median score at baseline. EQ-VAS score on the self-rated “thermometer,” indicating the patient's own assessment of their health status from 0 (worst) to 100 (best) imaginable health state.</description>
          <population>ITT population. Number subjects with evaluable data: (n=sunitinib, placebo)</population>
          <units>score on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 28 (n=187, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-60.0" upper_limit="70.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-50.0" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=148, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-60.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30.0" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=132, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-50.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-80.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=102,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-58.0" upper_limit="32.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-75.0" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=91,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" lower_limit="-55.0" upper_limit="42.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-75.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=73,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-65.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-10.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Health State Profile Index</title>
        <description>Change: median index score at observation minus median index score at baseline. EQ-5D is a generic instrument that describes health status in 5 dimensions (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) with a weighted health Index based on general population values where where 0.0 = death and 1.0 = perfect health.</description>
        <time_frame>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</time_frame>
        <population>ITT Population. Number subjects with evaluable data: (n=sunitinib, placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Double-Blind Treatment</title>
            <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Double-Blind Treatment</title>
            <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Health State Profile Index</title>
          <description>Change: median index score at observation minus median index score at baseline. EQ-5D is a generic instrument that describes health status in 5 dimensions (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) with a weighted health Index based on general population values where where 0.0 = death and 1.0 = perfect health.</description>
          <population>ITT Population. Number subjects with evaluable data: (n=sunitinib, placebo)</population>
          <units>score on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 28 (n=185, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.008" upper_limit="0.736"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.655" upper_limit="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=149, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.244" upper_limit="0.603"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.603" upper_limit="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=129, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" lower_limit="-1.008" upper_limit="0.603"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.694" upper_limit="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=104, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.694" upper_limit="0.639"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.655" upper_limit="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=91, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" lower_limit="-1.175" upper_limit="0.736"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.655" upper_limit="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=74, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.768" upper_limit="0.603"/>
                    <measurement group_id="O2" value="0.059" lower_limit="-0.152" upper_limit="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib Double-Blind Treatment</title>
          <description>Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Double-Blind Treatment</title>
          <description>Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.</description>
        </group>
        <group group_id="E3">
          <title>Sunitinib Open-Label Treatment</title>
          <description>Subjects experiencing disease progression could have their treatment assignment unblinded, and subjects who had been receiving placebo could crossover to open-label treatment with sunitinib; subjects who had been receiving sunitinib during double-blind treatment of the study could continue to do so after unblinding if, in the opinion of the investigator, there was sufficient evidence of clinical benefit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83"/>
                <counts group_id="E2" subjects_affected="27"/>
                <counts group_id="E3" subjects_affected="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mitral valve imcompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Duodenal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhagic tumour necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hepatic embolisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="223"/>
                <counts group_id="E2" subjects_affected="110"/>
                <counts group_id="E3" subjects_affected="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hand and foot syndrome secondary to sickle cell anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Splinter haemorhages</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lacrimal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Orbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Scleral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral mucosal discolouration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue blistering</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cheilosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Steatorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Duodenal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Enamel anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tooth erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter site discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter site excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Foetor hepaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nipple infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Necrotising ulcerative gingivostomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctitis monilial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Radiation oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Post gastric surgery syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Postoperative constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutrophil count normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bacterial culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mean cell volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multiple gated acquisition scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Venous pressure jugular increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vitamin B12 decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cow's milk intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhagic tumour necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vascular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Asterixis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intention tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysphemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Psychomotor retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Residual urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Menstruation delayed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pelvic discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vulval ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Genital erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Penile oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Acrodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Plantar erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin depigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Subcutaneous nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hair growth abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin chapped</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumatic compression therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cyst drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hepatic embolisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Mediastinal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Packed red blood cell transfusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Duration of Tumor Response could not be reliably estimated at the time of analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

